Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial.

Study answer

What this study found

AdoMet did not significantly change plasma homocysteine compared with placebo and was generally well tolerated. In the AdoMet arm, homocysteine was 8.3 at baseline, 8.8 at week 2, and 8.2 at week 4; between-group p-values for homocysteine were 0.18 at baseline, 0.26 at week 2, and 0.32 at week 4. The authors concluded that 800 mg/day for 4 weeks did not meaningfully affect homocysteine, inflammation, or lipid markers, aside from minor changes in ALT and total cholesterol.

Study & population

Double-blind, placebo-controlled, randomized clinical trial at Mayo Clinic in Rochester, Minnesota, United States.

Intervention

S-adenosyl-L-methionine (AdoMet) was given at 800 mg/day for 4 weeks, in tablet form, compared with placebo.

Key limitation

Small sample size, short 4-week duration, and enrollment of healthy volunteers limit generalizability.

View full study detailsView sourceOpen PDF

Original abstract